The Foundation is dedicated to advancing research in canine cancer immunotherapy. Our goal is to fund innovative studies that explore how a dog's immune system can be harnessed to combat cancer more effectively. By supporting rigorous scientific research, we aim to improve treatment options, enhance quality of life, and ultimately extend the lives of dogs affected by cancer.
Hans is a trained oncologist with experience in Germany, Canada, and the US. From 1995-2013, he directed Cancer Departments at Rush University in Chicago and Tufts University in Boston. At the University of British Columbia, he established the Natural Killer cell line NK-92, now widely used in cancer research and treatment. After academia, he served as Chief Science Officer for ImmunityBio and co-founded ZelleRx Inc. Hans has published over 200 scientific papers, with a strong focus on cancer immunotherapy.
Hans is a trained oncologist with experience in Germany, Canada, and the US. From 1995-2013, he directed Cancer Departments at Rush University in Chicago and Tufts University in Boston. At the University of British Columbia, he established the Natural Killer cell line NK-92, now widely used in cancer research and treatment. After academia, he served as Chief Science Officer for ImmunityBio and co-founded ZelleRx Inc. Hans has published over 200 scientific papers, with a strong focus on cancer immunotherapy.
Hans is a trained oncologist with experience in Germany, Canada, and the US. From 1995-2013, he directed Cancer Departments at Rush University in Chicago and Tufts University in Boston. At the University of British Columbia, he established the Natural Killer cell line NK-92, now widely used in cancer research and treatment. After academia, he served as Chief Science Officer for ImmunityBio and co-founded ZelleRx Inc. Hans has published over 200 scientific papers, with a strong focus on cancer immunotherapy.
Hans is a trained oncologist with experience in Germany, Canada, and the US. From 1995-2013, he directed Cancer Departments at Rush University in Chicago and Tufts University in Boston. At the University of British Columbia, he established the Natural Killer cell line NK-92, now widely used in cancer research and treatment. After academia, he served as Chief Science Officer for ImmunityBio and co-founded ZelleRx Inc. Hans has published over 200 scientific papers, with a strong focus on cancer immunotherapy.
Cancer remains the leading cause of death in dogs, tragically affecting nearly half of all dogs over the age of ten. Older dogs often don't tolerate traditional cancer treatments like chemotherapy and radiation as well as younger dogs. In many cases, the benefit of these aggressive approaches amounts to only a few extra weeks or months of life, often at the cost of significantly diminished quality of life. These harsher treatments can also compromise a dog's immune system, a critical factor in fighting cancer and preventing its spread. Our foundation supports innovative research focused on empowering a dog's own immune system to combat cancer. We believe that strengthening and supporting cancer-fighting immune cells is key to both extending life and maintaining quality of life. To achieve this, the Foundation provides grant funding to academic researchers dedicated to developing novel immune-based cancer therapies. We also support research that rigorously tests the efficacy of existing treatments, seeking to identify and promote the most promising approaches.